-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $3 Price Target

Benzinga·03/21/2025 12:21:11
Listen to the news
HC Wainwright & Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and maintains $3 price target.